Personalized Medical Devices Working Group

Stephanie Shedd

International Policy Analyst

U.S. FDA



Personalized Medical Devices Working Group

Established December 2020; 26 members from 12 jurisdictions

• Objectives:

- To develop technical guidance documents and harmonized recommendations for regulating PMDs across various jurisdictions
- To engage with stakeholders in the development, adoption, and implementation of the recommendations
- Eighteen virtual meetings since December 2020
- Objectives align with IMDRF Strategic Plan 2021-2025
 - Priority 1 Pre-market
 - Priority 3 Relationships with Stakeholders





1DRF 2024 Chair

Personalized Medical Devices Working Group

Public Consultations were undertaken to develop the following publications:

1. Definitions for Personalized Medical Devices (IMDRF/ PMD WG/ N49)

Published November 2018

2. Personalized Medical Devices - Regulatory Pathways (<u>IMDRF/ PMD WG/</u> <u>N58</u>)

First published April 2020; Revised version published in September 2023

3. Personalized Medical Devices - Production V&V (<u>IMDRF/ PMD WG/ N74</u>) Published April 2023





Personalized Medical Devices Working Group

Training Materials for PMD Stakeholders (NWIE)

- A Proposal will be discussed with the IMDRF MC in March 2024 to develop training materials for PMD stakeholders
- PMD documents present new definitions and concepts for regulation of PMDs and point-of-care manufacturing of medical devices
- If agreed by the IMDRF MC, the WG intends to:
 - promote the three IMDRF PMD documents and educate stakeholders
 - develop in collaboration with relevant stakeholders, artefacts to assist in training for regulators and industry (eg: PPT, video, Q&As)
 - monitor implementation and collect feedback









United States of America

2024